Alona Zer1, Rebecca M Prince2, Eitan Amir2, Albiruni Abdul Razak2. 1. All authors: Princess Margaret Cancer Centre, and University of Toronto, Toronto, Ontario, Canada. alonaz@clalit.org.il. 2. All authors: Princess Margaret Cancer Centre, and University of Toronto, Toronto, Ontario, Canada.
Abstract
PURPOSE: Randomized controlled trials (RCTs) in soft tissue sarcoma (STS) have used varying end points. The surrogacy of intermediate end points, such as progression-free survival (PFS), response rate (RR), and 3-month and 6-month PFS (3moPFS and 6moPFS) with overall survival (OS), remains unknown. The quality of efficacy and toxicity reporting in these studies is also uncertain. METHODS: A systematic review of systemic therapy RCTs in STS was performed. Surrogacy between intermediate end points and OS was explored using weighted linear regression for the hazard ratio for OS with the hazard ratio for PFS or the odds ratio for RR, 3moPFS, and 6moPFS. The quality of reporting for efficacy and toxicity was also evaluated. RESULTS: Fifty-two RCTs published between 1974 and 2014, comprising 9,762 patients, met the inclusion criteria. There were significant correlations between PFS and OS (R = 0.61) and between RR and OS (R = 0.51). Conversely, there were nonsignificant correlations between 3moPFS and 6moPFS with OS. A reduction in the use of RR as the primary end point was observed over time, favoring time-based events (P for trend = .02). In 14% of RCTs, the primary end point was not met, but the study was reported as being positive. Toxicity was comprehensively reported in 47% of RCTs, whereas 14% inadequately reported toxicity. CONCLUSION: In advanced STS, PFS and RR seem to be appropriate surrogates for OS. There is poor correlation between OS and both 3moPFS and 6moPFS. As such, caution is urged with the use of these as primary end points in randomized STS trials. The quality of toxicity reporting and interpretation of results is suboptimal.
PURPOSE: Randomized controlled trials (RCTs) in soft tissue sarcoma (STS) have used varying end points. The surrogacy of intermediate end points, such as progression-free survival (PFS), response rate (RR), and 3-month and 6-month PFS (3moPFS and 6moPFS) with overall survival (OS), remains unknown. The quality of efficacy and toxicity reporting in these studies is also uncertain. METHODS: A systematic review of systemic therapy RCTs in STS was performed. Surrogacy between intermediate end points and OS was explored using weighted linear regression for the hazard ratio for OS with the hazard ratio for PFS or the odds ratio for RR, 3moPFS, and 6moPFS. The quality of reporting for efficacy and toxicity was also evaluated. RESULTS: Fifty-two RCTs published between 1974 and 2014, comprising 9,762 patients, met the inclusion criteria. There were significant correlations between PFS and OS (R = 0.61) and between RR and OS (R = 0.51). Conversely, there were nonsignificant correlations between 3moPFS and 6moPFS with OS. A reduction in the use of RR as the primary end point was observed over time, favoring time-based events (P for trend = .02). In 14% of RCTs, the primary end point was not met, but the study was reported as being positive. Toxicity was comprehensively reported in 47% of RCTs, whereas 14% inadequately reported toxicity. CONCLUSION: In advanced STS, PFS and RR seem to be appropriate surrogates for OS. There is poor correlation between OS and both 3moPFS and 6moPFS. As such, caution is urged with the use of these as primary end points in randomized STS trials. The quality of toxicity reporting and interpretation of results is suboptimal.
Authors: Paweł Sobczuk; Huber Bątruk; Paulina Wójcik; Krzysztof Iwaniak; Katarzyna Kozak; Piotr Rutkowski Journal: J Cancer Res Clin Oncol Date: 2022-07-01 Impact factor: 4.553
Authors: Sungmin Woo; Chong Hyun Suh; Andreas G Wibmer; Anton S Becker; Min Yuen Teo; Mithat Gönen; Hedvig Hricak; Howard I Scher; Michael J Morris; Hebert Alberto Vargas Journal: Clin Genitourin Cancer Date: 2021-11-15 Impact factor: 2.872
Authors: R L Jones; G D Demetri; S M Schuetze; M Milhem; A Elias; B A Van Tine; J Hamm; S McCarthy; G Wang; T Parekh; R Knoblauch; M L Hensley; R G Maki; S Patel; M von Mehren Journal: Ann Oncol Date: 2018-09-01 Impact factor: 32.976
Authors: Marion Savina; Axel Le Cesne; Jean-Yves Blay; Isabelle Ray-Coquard; Olivier Mir; Maud Toulmonde; Sophie Cousin; Philippe Terrier; Dominique Ranchere-Vince; Pierre Meeus; Eberhard Stoeckle; Charles Honoré; Paul Sargos; Marie-Pierre Sunyach; Cécile Le Péchoux; Antoine Giraud; Carine Bellera; François Le Loarer; Antoine Italiano Journal: BMC Med Date: 2017-04-10 Impact factor: 8.775
Authors: Marion Savina; Saskia Litière; Antoine Italiano; Tomasz Burzykowski; Franck Bonnetain; Sophie Gourgou; Virginie Rondeau; Jean-Yves Blay; Sophie Cousin; Florence Duffaud; Hans Gelderblom; Alessandro Gronchi; Ian Judson; Axel Le Cesne; Paul Lorigan; Joan Maurel; Winette van der Graaf; Jaap Verweij; Simone Mathoulin-Pélissier; Carine Bellera Journal: Oncotarget Date: 2018-10-02